Daniel C Danila
Overview
Explore the profile of Daniel C Danila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
4708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Smith M, Scher H, Sandhu S, Efstathiou E, Lara Jr P, Yu E, et al.
Lancet Oncol
. 2022 Feb;
23(3):362-373.
PMID: 35131040
Background: Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP proteins. We evaluated the anti-tumour activity...
12.
Autio K, Antonarakis E, Mayer T, Shevrin D, Stein M, Vaishampayan U, et al.
Eur Urol Open Sci
. 2021 Dec;
34:70-78.
PMID: 34934969
Background: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently...
13.
Stopsack K, Nandakumar S, Arora K, Nguyen B, Vasselman S, Nweji B, et al.
Clin Cancer Res
. 2021 Oct;
28(2):318-326.
PMID: 34667026
Purpose: Black men die from prostate cancer twice as often as White men, a disparity likely due to inherited genetics, modifiable cancer risk factors, and healthcare access. It is incompletely...
14.
Brown L, Halabi S, Schonhoft J, Yang Q, Luo J, Nanus D, et al.
Clin Cancer Res
. 2021 Apr;
27(14):4077-4088.
PMID: 33820782
Purpose: While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts...
15.
Armstrong A, Luo J, Nanus D, Giannakakou P, Szmulewitz R, Danila D, et al.
JCO Precis Oncol
. 2020 Nov;
4.
PMID: 33154984
Purpose: Androgen receptor splice variant 7 (AR-V7) detection in circulating tumor cells (CTCs) is associated with a low probability of response and short progression-free (PFS) and overall survival (OS) in...
16.
Szymaniak B, Facchini L, Giri V, Antonarakis E, Beer T, Carlo M, et al.
JCO Oncol Pract
. 2020 Sep;
16(12):811-819.
PMID: 32986533
Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology...
17.
18.
Mota J, Barnett E, Nauseef J, Nguyen B, Stopsack K, Wibmer A, et al.
JCO Precis Oncol
. 2020 Aug;
4:355-366.
PMID: 32856010
Purpose: Alterations in DNA damage repair (DDR) genes occur in up to 25% of patients with metastatic castration-resistant prostate cancer (mCRPC) and may sensitize to platinum chemotherapy. We aimed to...
19.
Autio K, Klebanoff C, Schaer D, Kauh J, Slovin S, Adamow M, et al.
Clin Cancer Res
. 2020 Aug;
26(21):5609-5620.
PMID: 32847933
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macrophages. This phase I study evaluated...
20.
Stuopelyte K, Sabaliauskaite R, Bakavicius A, Haflidadottir B, Visakorpi T, Vaananen R, et al.
J Urol
. 2020 Apr;
204(1):77-78.
PMID: 32343215
No abstract available.